PCN85 PATIENT PREFERENCES IN THE THERAPY OF MULTIPLE MYELOMA  by Mühlbacher, AC et al.
asked to complete each assessment two days apart. The analyses
tested for mean differences (repeated measures ANOVA) and
reliability (intraclass correlation coefﬁcient [ICC]) to assess mea-
surement stability over time. Equivalence of the means was estab-
lished if the 95% conﬁdence interval (CI) of the mean difference
was within the minimally important difference (MID) interval:
-0.035 to .035 for the index and -3 to 3 for the EQ VAS.
Adequacy of the ICC was established by comparing the ICC 95%
lower CI with a critical value of 0.70. RESULTS: The per pro-
tocol analysis included 109 subjects for the EQ VAS and 113
subjects for the index. For the EQ-5D index, the means (SD) of
the paper and IVR administrations were 0.790 (0.172) and 0.800
(0.180), respectively. The 95% CI of the mean difference was
-0.024 to 0.006, which was within the equivalence interval. The
ICC was 0.894 (95% lower CI 0.857), signiﬁcantly different
from 0.70. For the EQ VAS, the means (SD) were 72.0 (19.7) for
paper and 74.1 (19.8) for IVR. The 95% CI of the mean differ-
ence was -3.784 to -0.484, partially within the equivalence
interval. The ICC was 0.897 (95% lower CI 0.859) also signiﬁ-
cantly different from 0.70. CONCLUSIONS: This analysis pro-
vides evidence that the EQ-5D scores on the IVR version were
equivalent to those obtained on the original paper version.
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OBJECTIVES: Cancer-related fatigue (crF) is a frequently
reported complaint in cancer patients and survivors. The Perform
Questionnaire (PQ) is a recently validated 12-item scale to assess
perceptions and beliefs about crF throughout the dimensions
‘Physical limitations’, ‘Activities of daily living’, ‘Beliefs and atti-
tudes’. This study aims to explore the performance of different
ways for identifying stable patients in the assessment of test-retest
reliability. METHODS: Patients with a moderate level of crF
participated in an observational and longitudinalmulti-centre. PQ
and a 100 mm horizontal visual analogue scale for fatigue inten-
sity (VAS) were administered at inclusion and 3 months later.
Stability concerning crF was deﬁned as either: 1) absence of
self-reported health change, using a standard self-administered
health status item (HSI) at the second visit on a Likert-type ordinal
scale with 13 response options, or 2) Fatigue VAS score change
between visits <5 mm. Test-retest reliability (Intraclass correlation
coefﬁcient, ICC) was assessed for the PQ overall and for the three
dimension scores, using each method 1 and 2.RESULTS: Baseline
sample characteristics (n = 437) were: 60.5% women, mean age
59.1 years, an average of 2.21 years since diagnosis, 33.6% breast
cancer, 54.7% with metastasis, Karnofsky mean score 80.9, and
29.1% with anaemia. ICC values obtained using the method 1
(n = 58) didn’t reach the standard value recommended (0.70) for
the overall (0.68) neither the dimension scores (0.52–0.68), while
ICC values obtained using themethod 2 (n = 64) were satisfactory
and reached the standards accepted for this psychometric proper-
tie assessment (0.83 for the overall score and ranging between
0.77 and 0.84 for the three dimension scores). CONCLUSIONS:
Patient-perspective is a relevant approach in the assessment of the
psychometric properties of the patient-oriented health outcomes
measures. The performance and adequacy of different patient-
perspective criteria can conduct to different conclusions concern-
ing speciﬁc psychometric properties.
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OBJECTIVES: Among patients with cancer and other diseases,
pain is a common experience that can negatively impact daily
living. It is unclear whether pain experiences and their impact are
diagnosis-speciﬁc or shared across conditions. We examined
whether the United States general population-based PROMIS
Pain Impact item bank can be used for measuring cancer pain,
and the relationship between pain experience and pain impact.
METHODS: PROMIS Pain Impact items included in ﬁeld testing
with oncology populations were selected through expert consen-
sus. Multidisciplinary clinical input was obtained to ensure
content coverage and the relevance of PROMIS pain items to
cancer. Items’ psychometric properties were reviewed when
applicable. As a result, PROMIS-Ca Pain Impact consisted of 36
items across 3 areas: physical, emotion and social. The sample
included 529 cancer patients (74% female, 82% White, mean
age = 56). Analyses included item scalability (item-scale correla-
tion >0.3), unidimensionality (exploratory and conﬁrmatory
factor analysis, and multidimensional scaling), and IRT model ﬁt
(S2-G2 & S2-X2). RESULTS: All 36 PROMIS-Ca Pain Impact
items met preset analysis criteria to form a unidimensional item
bank. Additional analyses showed that scores from Pain Impact
were signiﬁcantly correlated with Pain Quality items assessing
pain intensity (r = 0.56), frequency (r = 0.58) and duration
(r = 0.64), and could signiﬁcantly differentiate patients with dif-
ferent degrees of neuropathic pain, F(4527) = 37.4, p < 0.0001,
emotional distress as measured by two items F(4472) = 122.53,
p < 0.001, and F(4453) = 74.94, p < 0.001. Similar results were
found regardless of whether patients based their responses on
their “worst” or “least” pain experience. CONCLUSIONS:
PROMIS-Ca Pain is a psychometrically-sound and clinically
meaningful measure for cancer patients. It is correlated with
patients’ pain experience. Our next step is to examine whether
the same conclusion can be made with other disease groups.
Ultimately, a statistical cross-walk of pain scores could be created
to enable the comparison of pain scores between disease groups.
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OBJECTIVES: Analyses of patients’ preferences about their
therapies are a prerequisite for shared decision making, but are
still not widely performed. This study elaborates the importance
of treatment aspects in the eyes of multiple myeloma (MM)
patients using direct assessment and Discrete-Choice-
Experiments (DCE). METHODS: After a literature review we
conducted focus groups with 6–8 MM patients to collect the
most important therapy aspects. Then, patients answered an
online or paper-pencil questionnaire which asked for sociodemo-
graphic data, self-rated-health (SF12v2 variation) and patients’
preferences about therapy. The latter were assessed using direct
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measurement (16 items, 5-point Likert-scale) as well as DCE (8
pairs with 8 characteristics). The DCE pairs were generated at
random. Analyses of variance, inﬂuencing factors, random effect
probit and logit models for the DCE were performed. RESULTS:
282 patients responded of which 54% were male: mean age 62
years (SD = 10 years), mean duration of the disease ﬁve years
(SD = 3.8 years). Direct measurement revealed efﬁcacy aspects
and further treatment options as most important followed by
prolonged life expectancy, less side effects, therapy-free-intervals
and ﬂexibility. All aspects showed mean values above 50 points
(scale 0–100). In the DCE, alternatives which especially con-
tained one or more of the aspects further treatment options,
longer life expectancy, “Not-always-think-of-the-disease” and
therapy-free-intervals were more frequently selected than others.
CONCLUSIONS: Further treatment options are of major impor-
tance to MM patients. In addition, patients value treatment-free-
lifetime and emotional quality especially if they are not
continuously reminded of the disease. Combining direct mea-
surement of patients preferences with choice based measure-
ments like the DCE ensures eliciting important treatment aspects
and avoids ceiling effects and “all-is-very-important” results.
REMARKS: Patient-advocacy-groups Arbeitsgemeinschaft
Plasmozytom/Mulitples Myelom and Deutsche Leukämie- &
Lymphom-Hilfe helped organizing the surveys.
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OBJECTIVES: Prostate cancer is the second leading cause of
cancer mortality in American men. Androgen deprivation
therapy (ADT) is the standard initial treatment for advanced
disease, but most patients eventually develop HRPC. There are
no universally accepted, standardized and objective criteria for
assessing response to treatment for HRPC, so patient-reported
outcomes (PRO) are a critical in guiding and monitoring pallia-
tive interventions. We characterized the prevalence and natural
history of symptoms in patients with hormone refractory, incur-
able prostate cancer. METHODS: Patients with HRPC receiving
care at Dana-Farber Cancer Institute, completed a questionnaire
at each clinic visit over 10 months, comprising the Quality of Life
Index (QLI), Rotterdam Symptom Checklist (RSCL), Brief Pain
Inventory (BPI), Hospital Anxiety and Depression Scale (HADS),
American Urological Association symptom index (AUA), and the
ECOG performance status scale. RESULTS: A total of 87 of 102
eligible patients enrolled. Among participants, the survey
response rate was 98%. A total of 87% had documented
metastases; the remainder had rising prostate speciﬁc antigen
levels despite ADT. The following frequencies of symptoms were
reported at baseline and during follow-up (worst scores ever),
respectively: urinary symptoms, moderate/severe: 62 v. 75%; any
pain, 67 v. 70%; severe intensity in worst pain score, 19 v. 25%;
HADS possible/probable diagnosis: anxiety, 21 v. 39%, depres-
sion, 20 v. 35%; ECOG PS 2+, 15 v. 37%; RSCL symptoms:
tiredeness, 30 v. 60%; lack of energy, 28 v. 58%; muscle soreness,
26 v. 45%. The mean overall health rating (0 = worst,
100 = best) was, 74 at baseline v. 56 during follow up. A shift
toward lower levels of HRQL was also observed across all
domains of the QLI. CONCLUSIONS: Patients with HRPC
endure a substantial and worsening symptom burden over time.
Given the high prevalence of symptoms and difﬁculty of assessing
treatment response by objective measures in this disease, PRO
should be routinely incorporated into clinical care and trials.
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OBJECTIVES: Panitumumab, a fully human anti-EGFr mono-
clonal antibody, is approved in Europe as monotherapy for
mCRC patients with wild-type (non-mutated) KRAS tumors. In
a randomized phase 3 trial, chemorefractory mCRC patients
receiving panitumumab plus BSC had signiﬁcantly longer
progression-free survival vs. BSC alone. Analyses of the KRAS
gene showed that all responders had wild type KRAS. This
analysis evaluates patient-reported outcomes (PROs) by KRAS
status. METHODS: In the phase 3 trial, mCRC patients with
disease progression after standard chemotherapy were random-
ized 1:1 to panitumumab (6 mg/kg Q2W) plus BSC vs. BSC
alone. KRAS status was assessed in 427/463 (92%) patients.
Analyses of PROs included HRQOL (EQ-5D) and CRC symp-
toms (NCCN/FACT CRC Symptom Index, FCSI). Linear mixed
models estimating change from baseline in PRO scores were
employed. Sensitivity analysis using pattern-mixture models
evaluated the appropriateness of the assumption that PRO data
were missing at random. Pattern-mixture models can provide
unbiased estimates of treatment effects, taking into account
missing data patterns. ANCOVA of the time-adjusted AUC using
last value carried forward (LVCF) and slope imputation methods
were also used. RESULTS: There were 363/427 (85%) patients in
the KRAS-PRO analysis set (188 panitumumab [112 wild-type
KRAS; 76 mutant KRAS]; 175 BSC [96 wild-type KRAS; 79
mutant KRAS]). Linear mixed models showed signiﬁcant differ-
ences in CRC symptoms and HRQOL in favor of panitumumab
in patients with wild-type KRAS. No differences were observed
in patients with mutant KRAS. Pattern-mixture analysis showed
that signiﬁcant differences in CRC symptoms (FCSI scores: dif-
ference in LS adjusted means [95%CI]; 5.746 [1.448, 10.044]
and HRQOL (EQ-5D scores: difference in LS adjusted means
[95%CI]; 0.319 [0.184, 0.454]) in favor of panitumumab treated
patients with wild-type KRAS were particular to patients who
progressed greater or equal to 9 weeks. CONCLUSIONS: Pani-
tumumab patients with wild-type KRAS showed signiﬁcantly
better HRQOL and CRC symptoms compared to BSC alone.
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OBJECTIVES: Even though chemotherapies of advanced
non-small cell lung cancer (NSCLC) are improving patients’ out-
comes, usually patients’ treatment preferences are underesti-
mated by physicians. To identify those attributes related to
chemotherapy treatment that is highly valued by patients
with advanced NSCLC. METHODS: An observational, cross-
sectional study was carried out. A four attributes treatment
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